Corporate Presentation

Christopher U Missling, PhD | President & CEO

Nasdaq: AVXL | November 2020

Forward Looking Statement

This presentation contains forward-looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex® Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as “expects,” “plans,” “intends,” “believes,” “will,” “estimates,” “forecasts,” “projects,” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in reports filed by Anavex Life Sciences Corp. with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Anavex Life Sciences Corp. undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Anavex Life Sciences Corp. cannot be sure when or if it will be permitted by regulatory agencies to undertake clinical trials or to commence any particular phase of any clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Anavex Life Sciences Corp. will obtain regulatory approval for any “phase” of clinical trials. We also cannot be sure of the clinical outcome for efficacy or safety of our compounds. Potential investors should refer to the risk factors in our reports filed on Edgar.

Broad Pipeline Targeting Neurodegenerative and Neurodevelopmental Diseases with Significant Unmet Medical Need



- Differentiated clinical-stage CNS assets targeting significant and growing markets
- Patent protection to 2030-2039, worldwide rights for all product candidates

** = Orphan Drug Designation by FDA*

Targeting Large Market Opportunities with Significant Unmet Medical Need

All U.S. Patient Numbers



1) *Alzheimer's Disease Facts and Figures. Alzheimers Dement 2018;14(3):367-429.*
2) *Marras C et al 2018. npj Parkinson's Disease volume 4, Article number: 21*
3) *Based on prevalence number on orphanet*

Transformative Events for Anavex

- Rett Syndrome Program Received Fast Track Designation and is Eligible for Pediatric Priority Review Voucher
- Pursuing Large Markets with High Unmet Need by Applying Genetic Precision Medicine
- Novel CNS Mechanism of Action Upstream of Neurodevelopment and Neurodegeneration
- Compelling first Human Patient Data in Parkinson's Disease Dementia, Rett Syndrome and Alzheimer's Disease
- Sufficient Cash for >24 months To Achieve Key Milestones – Including non-dilutive Cash from Australian Government for Alzheimer's Trial, and from Rettsyndrome.org for Rett Syndrome Trial

Continued Significant Value-creating Events with Several Clinical Readouts in 2020/2021:

- Two Phase 2 Adult Rett Syndrome Trials (ClinicalTrials.gov Identifier: NCT03758924, NCT03941444)
- Phase 2/3 Pediatric Rett Syndrome Trial (ClinicalTrials.gov Identifier: NCT04304482)
- Phase 2b/3 Alzheimer's Disease Trial (ClinicalTrials.gov Identifier: NCT03790709)
- Phase 1 of ANAVEX®3-71 with focus on Frontotemporal Dementia (ClinicalTrials.gov Identifier: NCT04442945)

Catalysts to Drive Value

The company has multiple near-term clinical milestones

- ☑ Full enrollment Phase 2 Parkinson's disease dementia (PDD)
- ☑ Rett syndrome program received FDA Fast Track Designation and is eligible for FDA Pediatric Priority Review Voucher
- ☑ Initiate EXCELLENCE Phase 2/3 in pediatric Rett syndrome (RTT)
- ☑ Initiate Phase 1 ANAVEX®3-71
- ☑ Full enrollment U.S. Phase 2 RTT
- ☑ Topline data Phase 2 PDD
- ○ Topline data U.S. Phase 2 RTT – Q4 2020
- ○ Topline data AVATAR Phase 2 RTT – 1H 2021
- ○ Topline data Phase 1 ANAVEX®3-71 – 1H 2021

Clinical Trials – MoA and First Clinical Data:

- Rett Syndrome (RTT)
- Alzheimer’s Disease (AD)
- Parkinson’s Disease Dementia (PDD)

ANAVEX®2-73 MoA: S1R Activation is Upstream from other Therapeutic Targets



S1R = Sigma-1 Receptor

Neural cells suffer functional loss in neurological disorders which causes cellular stress

Pathologies include:

- ✓ **Aβ, Tau and ApoE** fragmentation and dysfunction
- ✓ **Proteinopathy**
- ✓ **Microglia** activation, migration, and dysregulation
- ✓ **Apoptosis** feedback loops that lead to neuronal degradation
- ✓ **Autophagy** dysfunction
- ✓ **Mitochondrial Dysfunction and Oxidative Stress** that leads to further neuronal degradation
- ✓ **Neurodegeneration** that spreads through a cascade of stress responses

S1R activates neuroprotective signals that help neurons return to homeostasis

ANAVEX®2-73 Establishes Human Proof-of-Concept and SIGMAR1 Target Occupancy

2D [18F]FTC-146-PET imaging of ANAVEX®2-73: Dose-dependent ANAVEX®2-73 Target Engagement



ANAVEX®2-73 positive response in functional (ADCS-ADL*) outcome in Alzheimer's disease patients correlate with SIGMAR1 mRNA levels



*Source: Reyes S et al, AAIC 2018; Hampel H et al. Alzheimer's Dement. 2020;00:1–14; *Alzheimer's Disease Cooperative Study Activities of Daily Living 23-item scale (ADCS-ADL)*

SIGMAR1 Activation has been Shown to Modulate Multiple Aspects of Neurodegenerative Processes

Sigma-1 receptor agonists have been shown to restore neuronal functions in neurodegenerative processes

Journal of Pharmacological Sciences

Critical review

Role of sigma-1 receptors in neurodegenerative diseases

Linda Nguyen, Brandon P. Lucke-Wold, Shona A. Mookerjee, John Z. Cavendish, Matthew J. Robson, Anna L. Scandiuzzi, Rae R. Matsumoto

ANAVEX®2-73 enhances autophagy and alleviates Tau pathology in neurodegenerative disease models



cells

MDPI

Article

Sigma-1 Receptor Activation Induces Autophagy and Increases Proteostasis Capacity In Vitro and In Vivo

Maximilian G. Christ, Heike Hussmann, Heike Nagel, Andreas Kern and Christian Behl

Blockade of Tau Hyperphosphorylation and $A\beta_{1-42}$ Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ_1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer's Disease

Sigma-1 receptor agonists have a neuroprotective effect in neurodegenerative disease models

REVIEW ARTICLE

Front. Neurosci. | doi: 10.3389/fnins.2019.00862

Neuronal Sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases

Daniel A. Ryskamp, Svetlana Korban, Vladimir Zhemkov, Nina Kraskovskaya and Ilya Bezprozvanny

Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity

Agostino Marrazzo, Filippo Caraci, Elisa Trovato Salinaro, Teung-Ping Su, Agata Copani and Giuseppe Ronsisvalle

What is Rett Syndrome?

Devastating neuro-developmental disease in girls with both movement impairment and cognitive impairment

Rett Syndrome (RTT)

- **Non-inherited genetic postnatal disorder caused by mutations in the MECP2 gene**
  - Occurs almost exclusively in girls
  - Leads to severe impairments, affecting nearly every aspect of the child's life
  - Impairment includes ability to speak, walk, eat and even breathe easily
  - Hallmark of RTT is near constant repetitive hand movements while awake
  - Occurs worldwide in approximately one in every 10,000 to 15,000 live female births

Source: https://www.rettsyndrome.org/about-rett-syndrome

Phase 2 PART A: Improvement in All Key Domains

U.S. Rett Syndrome ANAVEX®2-73-RS-001 Trial (NCT03758924)

SUMMARY

- Phase 2, safety, tolerability, efficacy for 7 weeks, oral, liquid formulation, 5 mg daily (relatively low dose)
- Part A: Intensive PK, n=6, **Completed**
- Part B: Randomized, double-blind, placebo-controlled, n=25, ongoing
- Females > 18 years, classic RTT w/MECP2 mutation
- Evaluations at baseline (Week 0), Week 4 & Week 7 (End of Treatment)
- Good safety and tolerability: No serious adverse events, only three grade 1-2 adverse events

EFFICACY*

- **Global severity RSBQ and CGI-I**
  RSBQ = Rett Syndrome Behavior Questionnaire
  CGI-I = Clinical Global Impressions – Improvements
- Secondary: Behavior (ADAMS), Sleep (CSHQ), VAS (top caregiver concerns), Seizure diary
- **Response Biomarker*: Glutamate, GABA**; Genetic biomarker: DNA & RNA profiles









Preliminary evaluation of efficacy: two-tailed, nonparametric tests (conservative)



Precision Medicine



Thomas DW et al. Clinical Development Success Rates 2006-2015. BIO Industry Analysis

In patients with RTT, MeCP2 deficiency leads to *increased* levels of Glutamate, in comparison to healthy controls[1,2,3], which results in excitatory-inhibitory imbalance and further synaptic dysfunction

Loss of synaptic homeostasis can impair nerve cells (neurons) and their connections

Glutamate as potential biomarker of microglia activation and synaptic dysfunction

1) Hamberger, A., et al., Elevated CSF glutamate in Rett syndrome. Neuropediatrics, 1992. 23(4): p. 212-3.;2) Lappalainen, R. and R.S. Riikonen, High levels of cerebrospinal fluid glutamate in Rett syndrome. Pediatr Neurol, 1996. 15(3): p. 213-6; 3) J.L. Neul at al., Metabolic signatures differentiate Rett syndrome from unaffected siblings. Frontiers in Integrative Neuroscience (2020) Vol14, Art 7, doi:10.3389/fnint.2020.00007

Phase 2 PART A: Reported Improvements Correlate with Biomarkers

U.S. Rett Syndrome ANAVEX®2-73-RS-001 Trial (NCT03758924)

REPORT on PART A: INTENSIVE PK SUBCOHORT

- Plasma levels of the biomarker Glutamate decreased significantly (Week 0 vs. Week 7; 2-tailed Wilcoxon signed rank test, p = 0.046)
- Levels of Glutamate at Week 7 directly correlated with CGI-I scores at Week 7 (2-tailed Spearman's rho = 0.837, p = 0.038)
- Greater decreases in Glutamate associated with greater improvement in these efficacy scores
- GABA changes demonstrated an inverse correlation of the magnitude of Glutamate changes (2-tailed Spearman's rho = -0.829, p = 0.042)



Significant Correlations: RSBQ & CGI-I



Glutamate & CGI-I



Glutamate & Hand Behaviors



Glutamate & Sleep



ANAVEX®2-73 Phase 2 U.S. Rett Syndrome Study

N=31* 

7 WEEK STUDY

RTT patient population

- Diagnosis of confirmed RTT
- Patients age >18
- Entire DNA and RNA sequencing

Randomization 3:2

ANAVEX®2-73 **Active dose#**

Placebo

Primary and Secondary Endpoints

- PK, safety and tolerability of ANAVEX®2-73
- Behavioral symptoms
- Sleep function
- Seizure activity

Pre-specified Endpoints

- Genetic variants SIGMAR1 (rs1800866), COMT (rs113895332/rs61143203) with influence on treatment effect

* Includes a 6 patient cohort undergoing a 7-week pharmacokinetic (PK) assessment with safety, tolerability, pharmacokinetic and efficacy evaluation of ANAVEX®2-73

 # Oral liquid solution once daily; Dose restricted to maintain complete blinding

ANAVEX®2-73 Phase 2 Rett Syndrome AVATAR Study

N=33*

7 WEEK STUDY

RTT patient population

- Diagnosis of confirmed RTT
- Patients age >18
- Entire DNA and RNA sequencing

Randomization 3:2

ANAVEX®2-73 **Active dose#**

Placebo

Primary and Secondary Endpoints

- Safety and tolerability of ANAVEX®2-73
- Behavioral symptoms
- Sleep function
- Seizure activity

Pre-specified Endpoints

- Genetic variants SIGMAR1 (rs1800866), COMT (rs113895332/rs61143203) with influence on treatment effect

* Includes a 3 patient cohort undergoing a 3-week pharmacokinetic (PK) assessment with safety, tolerability, pharmacokinetic and efficacy evaluation of ANAVEX®2-73

 # Oral liquid solution once daily; Dose restricted to maintain complete blinding

ANAVEX®2-73-RS-003 Rett Syndrome EXCELLENCE Study

N>69

12 WEEK STUDY

RTT patient population

- Diagnosis of confirmed RTT
- Patients age 5-18
- Entire DNA and RNA sequencing

Randomization 2:1

- ANAVEX®2-73 **Active dose#**
- Placebo

Primary and Secondary Endpoints

- Safety and tolerability of ANAVEX®2-73
- Behavioral symptoms
- Sleep function
- Seizure activity

Pre-specified Endpoints

- Genetic variants SIGMAR1 (rs1800866), COMT (rs113895332/rs61143203) with influence on treatment effect

 # Oral liquid solution once daily; Dose restricted to maintain complete blinding

Alzheimer's Disease (AD)

Alzheimer's disease is a progressive, irreversible neurological disease and the most common cause of dementia

Alzheimer's Disease (AD)

- **Alzheimer's disease incidence highly correlates with age**
  - AD prevalence in US:~5,700,000
  - Estimated 50 million people live with dementia worldwide
  - Today, there are no commercially available therapies to address the underlying cause of Alzheimer's
  - The current annual cost of dementia is estimated at $1 trillion, a figure set to double by 2030

Source: www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/parkinson-s-disease-dementia

ANAVEX®2-73 Demonstrated Improved MMSE[1] and ADCS-ADL[2] Scores in Phase 2a AD Study through 148 Weeks







Source: *Hampel et al. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. Alzheimer's Dement. 2020;00:1–14*

[1] Mini Mental State Examination (MMSE)
[2] Alzheimer's Disease Cooperative Study Group - Activities of Daily Living Inventory (ADCS-ADL)

ANAVEX®2-73 Phase 2b/3 Alzheimer's Disease and ATTENTION-AD OLE Study

N=450

48 WEEK STUDY
… and Open Label Extension (OLE) **96 weeks**

Early AD patient population

- Confirmed amyloid pathophysiology (CSF/amyloid PET)
- Patients aged 60 to 85 years
- MMSE score 20-28
- Entire DNA and RNA sequencing



Primary Endpoints
- ADAS-Cog
- ADCS-ADL
- Safety and tolerability of ANAVEX®2-73

Key Secondary Endpoints
- CDR-SB
- Structural and functional MRI
- Biomarkers: $Abeta_{40}$/$Abeta_{42}$, T-tau, P-tau, NFL, YKL-40, neurogranin, BACE1

Pre-specified Endpoints
- Genetic variants SIGMAR1 (rs1800866), COMT (rs113895332/rs61143203) with influence on treatment effect

 # Oral capsule once daily; Dose restricted to maintain complete blinding

Parkinson's Disease Dementia (PDD)

Up to 80 percent of those with Parkinson's disease eventually experience Parkinson's disease dementia

Parkinson's Disease Dementia

- **Parkinson's disease is a fairly common neurological disorder in older adults, estimated to affect nearly 2 percent of those older than age 65**
  - PD prevalence in US:~1,000,000
  - The brain changes caused by Parkinson's disease begin in a region that plays a key role in movement
  - Highly heterogeneous multisystem disorder
  - Etiology of cognitive impairment in PD has not yet been fully elucidated
  - As Parkinson's brain changes gradually spread, they often begin to affect mental functions, including memory and the ability to pay attention, make sound judgments and plan the steps needed to complete a task



Source: Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017 Apr;13(4):217-231. doi: 10.1038/nrneurol.2017.27. Epub 2017 Mar 3. PMID: 28257128; PMCID: PMC5643027; www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/parkinson-s-disease-dementia

ANAVEX®2-73 PoC Phase 2 PDD Study Design

A Phase 2 trial to Assess the Safety, Tolerability and Efficacy of ANAVEX®2-73 (*blarcamesine*) Oral Capsules in the Treatment of Parkinson's Disease Dementia



- **PDD Patient Population**
  - Diagnosis of probable Parkinson's disease dementia
  - Diagnosis of idiopathic Parkinson's disease
  - Patients aged ≥ 50 years
  - MoCA score 13-23
- **Key Primary and Secondary Endpoints**
  - Safety and tolerability
  - CDR Cognitive Domain of Attention
  - Sleep function
  - MDS-UPDRS
  - Actigraphy (24-hour monitoring)
  - Entire DNA and RNA sequencing
- **Pre-specified Endpoints**
  - Genetic variants SIGMAR1 (rs1800866),
  - COMT(rs113895332/rs6114320 3) with influence on treatment effect

ANAVEX®2-73-PDD-001 is a Proof of Concept (PoC) Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, 14-week study

Key Cognitive Domains

Key cognitive features addressed by ANAVEX®2-73 (*blarcamesine*)

The criteria from the National Institute on Aging and Alzheimer's Association (NIA-AA) workgroup mention the following five cognitive domains when diagnosing MCI-AD:

Addressed in PoC Phase 2 PDD Study

(a) Episodic memory

(b) Attention

(c) Language

(d) Visuospatial skills

(e) Executive functions

Related CDR system domains

- Episodic memory ✅
- Choice reaction time ✅
- Word recognition ✅
- Picture recognition ✅
- Numeric working memory ✅

Source: Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21. PMID: 21514249; PMCID: PMC3312027.

Significant Improvements in Episodic Memory with Increased Dose

ANAVEX®2-73-PDD-001 Study: Dose-dependent, statistically significant improvement of Quality of Episodic Memory with ANAVEX®2-73 (*blarcamesine*)



- A high score reflects ability to store, hold and retrieve information of an episodic nature (e.g., an event or name)
- CDR system Quality of Episodic Memory highly correlated (70%) with ADAS-Cog (r = 0.7)[1]

1. *Wesnes K, Edgar C, Andreasen N, Annas P, Basun H, Lannfelt L, et al. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease. Acta Neurol Scand 2010; 122:270–7*

All participants; ANAVEX2-73 = Active 30 mg, Active 50 mg vs Placebo
J-T test based on actual maintenance dose: p = 0.003

Summary of Topline Results:

Broad and Significant Effects with ANAVEX®2-73 (*blarcamesine*) in PDD Patients

- ANAVEX®2-73 (*blarcamesine*): a novel, oral, investigational sigma-1 receptor (Sig-1R / SIGMAR1) agonist with multimodal activity
- Data confirm SIGMAR1 as gene "signature" biomarker of response to ANAVEX®2-73 (*blarcamesine*) confirming SIGMAR1 activation as mechanism of action
- Broad and statistically significant improvements in CDR system Cognitive Domain of Attention assessed by Choice Reaction Time ($p = 0.039$) and Digital Vigilance ($p = 0.008$) and CDR system Episodic Memory ($p = 0.047$), representing complex cognitive tasks with impact on quality of life such as making a choice between similar objects and remembering daily personal experiences, which are mostly impaired in both PD and AD[1]
- Statistically significant dose-dependent ($p = 0.003$) improvement of CDR system Episodic Memory, which has been shown to be highly correlated (70%) with the Alzheimer's Disease Assessment Scale–Cognitive score (ADAS-Cog; $r = 0.7$)[2]
- ANAVEX®2-73 (*blarcamesine*) does not impair sleep and has a positive effect on REM sleep behavior disorder
- ANAVEX®2-73 (*blarcamesine*) was generally safe, well tolerated, and improved safety profile compared to dementia drugs associated with typical adverse effects
- These results support continued development in PDD / PD as well as currently ongoing Phase 2 and Phase 2/3 clinical studies with ANAVEX®2-73 (*blarcamesine*) in Rett syndrome[3] and Alzheimer's disease[4]
- Data will be submitted to the U.S. Food and Drug Administration to seek regulatory guidance

1. *Mahurin, R. K., & Pirozzolo, F. J. (1993). Application of Hick's law of response speed in Alzheimer and Parkinson diseases. Perceptual and Motor Skills, 77(1), 107–113*
2. *Wesnes K, Edgar C, Andreasen N, Annas P, Basun H, Lannfelt L, et al. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease. Acta Neurol Scand 2010; 122:270–7*
3. *ClinicalTrials.gov Identifiers: NCT03758924, NCT03941444, NCT04304482*
4. *ClinicalTrials.gov Identifiers: NCT03790709, NCT02756858*

Anavex is pursuing Large Markets by Applying Precision Medicine to Develop Treatments for *both* Global Aging CNS diseases (Alzheimer's, Parkinson's), as well as catastrophic Orphan Genetically caused diseases, Rett Syndrome with High Unmet Needs

$ 277B

Economic burden

2018 Alzheimer's Association

OVERARCHING MESSAGE

A novel approach is needed to address the totality of CNS diseases

PRECISION MEDICINE IMPROVES CHANCE OF CLINICAL SUCCESS

Testing for biomarkers demonstrated improved clinical response to ANAVEX®2-73 in Rett syndrome correlated with glutamate and for Alzheimer's and Parkinson's patients carrying wild-type (WT) SIGMAR1 gene

NOVEL CNS MECHANISM OF ACTION

ANAVEX®2-73, an orally available Sigma-1 receptor agonist, is upstream of neurodevelopment and neurodegeneration and has been shown to restore homeostasis

COMPELLING INITIAL HUMAN DATA

ANAVEX®2-73 Phase 2 Parkinson's disease dementia, ongoing Phase 2 in Rett syndrome and Phase 2a trial in Alzheimer's with favorable safety and initial efficacy results through 148 weeks

WORLDWIDE COMMERCIAL RIGHTS AND STRONG IP FOUNDATION

We retain global commercial rights to all of our product candidates and our lead product candidate, ANAVEX®2-73, including patent protection to 2030-2039



SUFFICIENT CASH TO ACHIEVE KEY MILESTONES

Sufficient cash for >24 months to achieve key milestones, including non-dilutive cash from Australian government for Alzheimer's trial and from Rettsyndrome.org for Rett syndrome trial

Anavex Life Sciences Expertise

Management Team

Christopher U. Missling PhD - President & CEO

Walter E Kaufmann, MD - Chief Medical Officer

Stephan Toutain, MS, MBA – Chief Operating Officer

Emmanuel O Fadiran, RPh, PhD - SVP of Regulatory Affairs

Daniel Klamer, PhD - VP of Business Development & Scientific Strategy

Scientific Advisory Board Members

Jeffrey Cummings, MD

Corinne Lasmezas, PhD

Ottavio Arancio, MD, PhD

Andrew Cole, MD

Daniel Weintraub, MD

Paul Aisen, MD

Norman Relkin, MD, PhD

Jacqueline French, MD

Dag Aarsland, MD, PhD

Tangui Maurice, PhD

Contact Us



Corporate Office

Anavex®Life Sciences Corp.
51 West 52nd Street, 7th floor
New York, NY 10019
1-844-689-3939

Shareholder & Media Relations

ir@anavex.com
www.anavex.com
NASDAQ: AVXL